COSCIENS Biopharma Inc (CSCI) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI...

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

TORONTO, ONTARIO, March 19, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

Company leveraging core competencies to develop and commercialize natural-based products to improve health and...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

COSCIENS Biopharma Announces Change to Board of Directors

TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI...

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]